CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,204 enrolled
Drug / intervention
Rate or Rhythm Control Therapy +1 moredrug
Likely dose
Rate or Rhythm Control Therapy 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00911508
NCT00911508N/ACompleted
CompareCT.gov

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Mayo Clinic·interventional·Posted Jun 2, 2009·Updated Apr 21, 2021

In Brief

A clinical study evaluating Left atrial ablation and Rate or Rhythm Control Therapy for Atrial Fibrillation and Arrhythmia. Completed, enrolled 2,204 participants across 118 sites in 10 countries.

Detailed Summary

The (Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial) CABANA Trial has the overall goal of establishing the appropriate roles for medical and ablative intervention for atrial fibrillation (AF). The CABANA Trial is designed to test the hypothesis that the treatment strategy of left atrial catheter ablation for the purpose of eliminating atrial fibrillation (AF) will be superior to current state-of-the-art therapy with either rate control or rhythm control drugs for decreasing the incidence of the composite endpoint of total mortality, disabling stroke, serious bleeding, or cardiac arrest in patients with untreated or incompletely treated AF.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation, Arrhythmia
CountriesAustralia, Canada, China, Czechia, Germany, Italy, Russia, South Korea, United Kingdom, United States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), Abbott Medical Devices, Biosense Webster, Inc.

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2, 2009
Enrollment StartNov 13, 2009
Primary CompletionDec 31, 2017
TodayJul 2, 2026
Enrollment to primary: 8.1 yearsPosted 17.1 years ago

Interventions

Left atrial ablationdevice

St. Jude: Livewire TC™ , Therapy™ Dual / Thermocouple, Safire,Therapy Cool Path Biosense Webster: NAVI-STAR, NAVI-STAR/NAVI-STAR DS, Celsius Braided/Long Tip, NAVI-STAR™ and Celsius™ ThermoCool, NAVI-STAR® RMT, Celsius® RMT, ThermoCool® SF Medtronic CryoCath LP: Freezor®/Freezor MAX®, Artic Front®, Cardiac Ablation System Bard: Stinger Boston Scientific: Blazer II RF/XP, Blazer RPM, Chilli II Cooled, SteeroCath

Rate or Rhythm Control Therapydrug

Rate control: Metoprolol 50-100mg, Atenolol 50-100mg, Propranolol 40-80mg, Acebutolol 200-300mg, Carvedilol 6.25-25mg, Diltiazem 180-240mg, Verapamil 180-240mg, Digoxin 0.125-0.25mg Rhythm control: Propafenone 450-625mg, Flecainide 200-300mg, Sotalol 240-320mg, Dofetilide 500-1000mcg, Amiodarone 200-400mg, Quinidine 600-900mg, Dronedarone 800mg